Melanoma Clinical Trials in Pittsburgh

Showing 101-120 of 161 trials

Melanoma Molecular Profiling Analysis

NCT00889980

There is a significant need to develop new and more effective ways to treat melanoma that will decrease patient morbidity and mortality. This protocol intends to collect and process a portion (\< 20% of any node) of lymph nodes from melanoma patients undergoing routine surgical SLN resection: the SLN(s) and 1 adjacent non-SLN(s) are planned for study. In addition, blood will be drawn at the pre study visit (serum and peripheral blood mononuclear cells) and appropriate lineage control tissue will be collected. Material only from already-indicated and planned procedures as part of standard medical care will be used. The main goal of this study will be to properly collect and process material to be analyzed and explore the molecular features melanoma biological samples.

Melanoma

University of Pittsburgh237 participantsStarted May 2008

Pittsburgh, Pennsylvania, United States

COMPLETEDPHASE1< 1 mile

Neoadjuvant Combination Therapy With Ipilimumab and HighDose IFN-α2b for Melanoma

NCT01608594

The purpose of this study is to evaluate the safety and potential effectiveness of a new treatment for advanced and recurrent melanoma involving the combination of Ipilimumab and IFN-α2b before surgery and to test for biomarker studies in blood and/or tumor to better understand this disease, how best to treat it and what patients should be treated with this combination.

Melanoma

Diwakar Davar30 participantsStarted May 2013

Pittsburgh, Pennsylvania, United States

Melanoma Molecular Profiling Analysis

Neoadjuvant Combination Therapy With Ipilimumab and HighDose IFN-α2b for Melanoma

Melanoma Trials in Other Cities

Phase 1 Study of GRN-1201 in HLA-A*02 Subjects With Resected Melanoma

A Study of Tasisulam in Treating Participants With Malignant Melanoma

Combination of Decitabine and Temozolomide in the Treatment of Patients With Metastatic Melanoma

Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors

Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma

A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers

In Situ, Autologous Therapeutic Vaccination Against Solid Cancers With Intratumoral Hiltonol®

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab

Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma

A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors

Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone

Phase 1b Safety Study of CMB305 in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1

LC Bead Embolization Agent With Doxorubicin in the Treatment Liver Metastasis From Melanoma

A Study of Intratumoral CAVATAK™ in Patients With Stage IIIc and Stage IV Malignant Melanoma (VLA-007 CALM )

Single-arm Trial to Evaluate the Biodistribution and Shedding of Talimogene Laherparepvec

A Personal Cancer Vaccine (NEO-PV-01) and APX005M or Ipilimumab With Nivolumab in Patients With Advanced Melanoma

A Study to Investigate the Effect of Itraconazole and Rifampin on Pharmacokinetics (PK) of Vemurafenib at Steady State

Other Conditions in Pittsburgh